Press ReleaseRelease DateDownload
TherapeuticsMD Announces Second Quarter 2015 Financial Results 8/6/2015
TherapeuticsMD receives patent allowance for VVA candidate TX-004HR 8/5/2015
TherapeuticsMD to Host Second Quarter 2015 Financial Results Conference Call and Webcast August 6 7/27/2015
TherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR (estradiol in VagiCap™) 6/9/2015
TherapeuticsMD, Inc. to participate in upcoming investor conferences 5/26/2015
TherapeuticsMD featured at the 10th European Congress on Menopause and Andropause 5/21/2015
TherapeuticsMD Inc. to present at upcoming investor conferences 5/6/2015
TherapeuticsMD announces first quarter 2015 financial results 5/5/2015
New data on compounded prescription practices show differences among medical specialties 5/4/2015
TherapeuticsMD to host first quarter 2015 financial results conference call and webcast May 5 4/22/2015
TherapeuticsMD appoints biopharmaceutical senior executives Angus C. Russell and J. Martin Carroll as independent directors 3/18/2015
TherapeuticsMD announces fourth quarter and full-year 2014 financial results 3/10/2015
Physicians’ visual assessments correlate with objective measurements of postmenopausal VVA patients treated with TX-004HR VagiCapTM 3/9/2015
Poster: Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can be Used to Assess Treatment Efficacy 3/6/2015
Poster: Menopausal Hormone Therapy (MHT) Usage: FDA-Approved MHT Has Decreased While Compounded Non-FDA-Approved MHT Has Increased 3/6/2015
TherapeuticsMD to host fourth quarter, full-year 2014 financial results conference call and webcast 2/24/2015
Survey shows postmenopausal women with VVA reported improved satisfaction and quality of life with VagiCapTM investigational local estrogen treatment 2/20/2015
TherapeuticsMD announces pricing of common stock offering 2/11/2015
TherapeuticsMD Announces Offering of Common Stock 2/10/2015
TherapeuticsMD receives five new patent allowances, further strengthens IP assets 12/15/2014
TherapeuticsMD ranks No. 1 among Florida companies in Deloitte Technology Fast 500 11/20/2014
TherapeuticsMD Inc. to present at the Stifel Healthcare Conference 11/14/2014
TherapeuticsMD announces third quarter financial results 11/6/2014
TherapeuticsMD to host third quarter 2014 financial results conference call and webcast November 6 10/23/2014
TherapeuticsMD announces oral presentation of positive phase 2 and bioavailability data on TX-004HR (VagiCapTM) 10/15/2014
TherapeuticsMD Inc. granted two new patents 9/30/2014
TherapeuticsMD begins phase 3 clinical trial of TX-004HR 9/29/2014
TherapeuticsMD announces second quarter 2014 financial results 8/6/2014
TherapeuticsMD to hold second quarter 2014 financial results conference call and webcast on August 6 8/1/2014
TherapeuticsMD announces pricing of offering of common stock 7/30/2014
TherapeuticsMD announces $40 million offering of common stock 7/29/2014
TherapeuticsMD to present at JMP HealthCare Conference 6/17/2014
TherapeuticsMD announces 2014 Investor Day webcast on June 16 6/10/2014
TherapeuticsMD announces release of RediChew and Prena1 Chew 5/28/2014
TherapeuticsMD announces 2014 Investor Day 5/27/2014
TherapeuticsMD to present at Jefferies 2014 HealthCare Conference 5/22/2014
TherapeuticsMD reports first quarter 2014 results 5/5/2014
TherapeuticsMD to present the design of its REPLENISH Trial at the IMS 14th World Congress 5/1/2014
TherapeuticsMD to present at Bank of America Merrill Lynch 2014 Health Care Conference 4/29/2014
TherapeuticsMD to host conference call and live audio webcast to disclose first quarter financial results 4/25/2014
TherapeuticsMD reports positive results of rabbit irritation study 4/7/2014
BocaGreenMD launches PRENA1 PEARL 4/6/2014
TherapeuticsMD announces pricing of secondary offering 3/20/2014
VitaMedMD launches vitaPearl 3/19/2014
TherapeuticsMD announces launch of secondary offering 3/18/2014
TherapeuticsMD reports fourth quarter and full-year 2013 results 3/3/2014
TherapeuticsMD announces conference call to disclose 2013 year-end results 2/25/2014
TherapeuticsMD to Present at Cowen & Co. 34th Annual Healthcare Conference 2/25/2014
TherapeuticsMD reports positive PK sudy results for its estradiol VagiCap™ (TX-004HR) 1/28/2014
TherapeuticsMD initiates phase 3 clinical trial of its progesterone candidate (TX-002HR) for treatment of secondary amenorrhea 1/24/2014
TherapeuticsMD announces issuance of U.S. patent covering TX-001HR 1/22/2014
TherapeuticsMD announces 50th site for phase 3 clinical trial of TX-001HR 1/6/2014
TherapeuticsMD names Randall S. Stanicky to Board of Directors 12/18/2013
TherapeuticsMD receives notice of allowance for patient covering platform technology... 12/9/2013
TherapeuticsMD appoints Joel S. Krasnow, M.D. as Chief Scientific Officer 12/4/2013
TherapeuticsMD to present at 25th annual Piper Jaffray Healthcare Conference 11/22/2013
TherapeuticsMD applauds congressional leadership on passage of Drug Quality and Security Act 11/19/2013
TherapeuticsMD reports third quarter 2013 financial results 11/4/2013
TherapeuticsMD appoints Sebastian Mirkin, M.D. as Chief Medical Officer 10/23/2013
VVA Phase 1 Results 10/22/2013
TherapeuticsMD Third Quarter Results Conference Call 10/21/2013
TherapeuticsMD, Inc. poster wins first-place prize at the North American Menopause Society 2013 Annual Meeting 10/18/2013
Phase 1 data on first oral combination 17β-Estradiol and Progesterone capsule being developed for FDA review 10/9/2013
TherapeuticsMD to present at 12th Annual BIO Investor Forum 10/4/2013
TherapeuticsMD announces pricing of offering of common stock 9/25/2013
TherapeuticsMD begins patient enrollment in pivotal phase 3 clinical trial of TX-001HR 9/5/2013
TherapeuticsMD to present at STIFEL NICOLAUS 2013 Healthcare Conference 8/29/2013
TherapeuticsMD Initiates Phase 1 Study Of Estradiol Vagicap™ 8/12/2013
TherapeuticsMD Reports 2nd Quarter 2013 Financial Results 8/6/2013
TherapeuticsMD, Inc. Added to 2013 Russell Indexes 7/1/2013
TherapeuticsMD to Present at JMP Securities Healthcare Conference 6/26/2013
TherapeuticsMD Investigational New Drug Filing Accepted By FDA 6/14/2013
TherapeuticsMD to Ring Opening Bell at NYSE 6/11/2013
TherapeuticsMD To Present Jefferies Conference 5/28/2013
TherapeuticsMD elects Jules A. Musing to Board of Directors 5/16/2013
TherapeuticsMD reports first quarter 2013 financial results 5/8/2013
TherapeuticsMD Announces Trading of its Common Stock on the NYSE MKT under symbol "TXMD" 4/19/2013
TherapeuticsMD Announces Pricing of Public Offering of Common Stock 3/15/2013
TherapeuticsMD announces $50,000,000 proposed public offering of common stock 3/7/2013
BocaGreenMD Inc. launches line of generic prescription prenatal multivitamins 11/1/2012
TherapeuticsMD, Inc. Announces $8.5 Million Private Placement 9/26/2012
TherapeuticsMD, Inc. Has IND Filing Accepted By FDA 8/7/2012
TherapeuticsMD, Inc. Launches vitaMedMD™ Iron 21/7, a Unique, Patient-friendly Iron Supplement 7/17/2012
TherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur with the Recent Joint Statement From NAMS, ASRM and the Endocrine Society 7/10/2012
TherapeuticsMD, Inc. Files for Two Additional Patents on Prescription Products For Treatment of Menopausal Symptoms & Related Conditions 6/21/2012
Tommy G. Thompson, Former U.S. Secretary of Health and Human Services, Joins TherapeuticsMD, Inc. as Chairman 5/16/2012
TherapeuticsMD, Inc. Launches VitaMedMD RediChew Rx, The First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic 5/10/2012
TherapeuticsMD, Inc. Launches VitaMedMD One Rx, The First Daily One Pill Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA 4/9/2012
TherapeuticsMD, Inc. Elects Four Additional Directors 3/2/2012
TherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, The First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA 3/2/2012
TherapeuticsMD, Inc. Launches Its First Prescription Prenatal Vitamin on March 1, 2012 2/7/2012
TherapeuticsMD, Inc. Acquires VitaMedMD, LLC 10/5/2011